M²OLIE (“Mannheim Molecular Intervention Environment“) is one of nine Research Campuses in Germany that have been funded by the Federal Ministry of Education and Research since 2012 as part of the “Research Campus – Public-Private Partnership for Innovation” Initiative. In June 2019, M²OLIE successfully entered the second of three possible funding phases (2019-2024).
The aim of M²OLIE is to establish the M²OLIE Closed Loop, a patient-centered and time-optimized infrastructure for innovative tumor therapies. By means of molecular intervention, the aim is to make treatment of cancer patients with oligometastases possible in a “one-stop shop”.
In a multidisciplinary development center, partners from industry, research and public life develop new methods for molecular imaging, diagnostics and therapeutic intervention of oligometastatic patients in clinical practice within the framework of three collaborative projects. A process model and a clinical process management system will ensure the efficiency of the treatment in a smooth closed-loop process. The establishment of the organizational procedure will ensure that the entire process from patient admission and diagnostics to the final therapeutic intervention and discharge of the patient can be carried out within a limited time frame.
The close networking of medical research, sciences, engineering, information science and business administration, and thus the overcoming of complexity barriers ensures the success of M²OLIE.
The M²OLIE Closed-Loop Process starts with the patient’s admission (left). In the next step, an electronic M²OLIE patient file is created using data from MIRACUM. The automated process control takes over and initiates an iterative path of different treatment stages: multimodal (pre-)interventional imaging, automated biopsy, molecular biopsy analysis, individualized minimally invasive therapy. The therapy decision is made as suggested by the digital expert system after the ad hoc tumor board (top center). After the therapy of each metastasis, the patient leaves the Closed Loop with or without subsequent drug tumor therapy (top right). The blue area symbolizes the data lake in which all data is stored, processed and made available on demand. Learn more.
The third and final funding phase focuses on completing the M²OLIE closed-loop process a comprehensively optimized diagnosis and therapy process for cancer patients with oligometastases. Four modules help to achieve this: the M²OLIE Operational Platform controls and integrates all process steps, the M²OLIE Intervention Platform module increases the efficiency and precision of interventions, the M²OLIE Laboratory focuses on the detailed analysis of tumor sites, and the M²OLIE Tumor Board will enable flexible, ad hoc case discussions in the future. The implementation of these modules forms the basis for the planned M²OLIE clinic and the transfer of results into clinical practice.
Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation
Mansour N, JoramJ, Grawe F, Hinterberger A, Rübenthaler J, Kunz WG, Winkelmann M, Cyran CC, Ricke J, Öcal O, Unterrainer...
read more
